Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002331 · ClinicalTrials.gov registry record · NA

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

A NA study of HIV Infections and Mycobacterium Avium-intracellular Infection, sponsored by Abbott.

Completed
Registry status
NA
Development phase
18
Study locations

NCT00002331: Completed NA study of HIV Infections and Mycobacterium Avium-intracellular Infection, sponsored by Abbott.

NCT00002331 is a NA study of HIV Infections and Mycobacterium Avium-intracellular Infection that has completed, run by Abbott. The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002331, a NA study of HIV Infections and Mycobacterium Avium-intracellular Infection, has completed, sponsored by Abbott.

COMPLETED
Registry status
NA
Development phase
18
Study locations

Study Summary

PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC). SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time required to achieve it. To determine the duration of bacteriological response, defined as length of time that blood cultures remain sterile.

Interventions

  • DRUG Clofazimine
  • DRUG Clarithromycin
  • DRUG Ethambutol hydrochloride

Study Locations (18)

California

  • Kaiser Permanente Med Ctr - Los Angeles
  • UCD Med Ctr - Sacramento
  • Kaiser Permanente Med Ctr - San Francisco
  • Santa Clara Valley Med Ctr - San Jose

Florida

  • Dr Margaret Fischel - Miami
  • Saint Joseph's Hosp / Infectious Disease Rsch Institute - Tampa

New York

  • Beth Israel Med Ctr - New York
  • Mount Sinai Med Ctr - New York

Texas

  • Univ of Texas Southwestern Med Ctr of Dallas - Dallas
  • Houston Veterans Administration Med Ctr - Houston

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.

Illinois

  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago

Louisiana

  • Tulane Univ Med School - New Orleans

Maryland

  • Johns Hopkins Univ School of Medicine - Baltimore

Trial Details

FieldValue
Start Date 1994-01
Est. Completion 1995-03
Phase NA
Abbott

181 total trials

What the finished NCT00002331 record still lists

NCT00002331 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Clofazimine is the first listed.

NCT00002331 lists 18 locations in 12 states (California, Florida, New York).

Frequently Asked Questions

What is clinical trial NCT00002331 about?

NCT00002331 is a clinical study titled "The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS". PRIMARY: To assess the tolerability of the combination regimen of clarithromycin plus ethambutol with or without clofazimine in patients with disseminated Mycobacterium avium Complex (dMAC). SECONDARY: To determine the proportion of patients achieving a sterile blood culture along with the time req...

What is the current status of trial NCT00002331?

This trial is currently completed. It is a NA study. The study started on 1994-01. Estimated completion is 1995-03.

What conditions does trial NCT00002331 study?

This clinical trial studies the following conditions: HIV Infections, Mycobacterium Avium-intracellular Infection.

What interventions are being tested in trial NCT00002331?

The interventions under investigation include: Clofazimine (DRUG), Clarithromycin (DRUG), Ethambutol hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002331?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002331 being conducted?

This trial has 18 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002331, the US trial registry maintained by the National Library of Medicine. NCT00002331 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.